Welcome to our dedicated page for Bausch Health Companies SEC filings (Ticker: BHC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bausch Health Companies Inc. filings document regulatory disclosures for a global diversified pharmaceutical company incorporated in British Columbia. The record includes Form 8-K reports for quarterly and annual operating results, Regulation FD updates, clinical-program disclosures, material agreements, debt exchanges and credit-agreement refinancing involving Bausch Health and its subsidiaries, including Bausch + Lomb.
Proxy materials describe annual meeting matters, director elections, auditor approval, executive compensation votes and governance procedures. Other current reports address compensatory arrangements, including performance share unit settlement terms, and capital-structure disclosures tied to senior secured notes, guarantees, collateral arrangements and refinancing transactions.
Bausch Health Companies Inc. executive vice president and CFO Jean-Jacques Charhon reported a tax-related share disposition. On the vesting of Restricted Share Units, 49,060 common shares at $5.93 per share were withheld to cover tax obligations, a non-market transaction. After this withholding, Charhon directly holds 706,478 common shares.
Bausch Health Companies Inc. EVP and General Counsel Seana Carson reported several equity transactions in the company’s common shares. She sold 6,856 shares on March 2, 2026 at $5.78 per share and 4,420 shares on March 3, 2026 at $5.77 per share in open-market sales under a pre-arranged Rule 10b5-1 trading plan. The filing also shows share dispositions used to cover tax withholding on vesting of restricted share units, and a cash settlement of 137,922 previously earned performance share unit awards under the company’s 2014 Omnibus Incentive Plan. After the most recent sale, Carson directly holds 616,761 common shares of Bausch Health.
Bausch Health Companies Inc. director and CEO Thomas Appio reported equity award-related transactions in common shares, no par value. On February 27, 2026 and March 2, 2026, the company withheld 83,093 and 83,705 shares, respectively, to satisfy tax withholding obligations upon vesting of restricted share units.
The filing also records an "other" transaction for 1,137,862 performance share unit awards that will be settled in cash rather than company stock, as approved by the board committee and previously disclosed. Following these transactions, Appio directly held 3,453,236 common shares on March 2, 2026.
BHC reported a Form 144 notice for proposed sales of common stock by an insider. The filing lists two sale transactions by Seana Carson: 8,388 shares on 02/27/2026 for $49,908.60 and 6,856 shares on 03/02/2026 for $39,627.68.
The filing also shows 4,420 shares tied to restricted stock vesting on 03/02/2026 labeled as Issuer / Compensation. The record lists a brokerage account at Fidelity Brokerage Services LLC.
Bausch Health Companies Inc. updated how certain 2023 performance share units (PSUs) for two senior executives will be paid out. These PSUs were granted in March 2023, tied to a three-year performance period, and are scheduled to vest on March 3, 2026.
For CEO Thomas Appio, the award agreement covering 1,137,862 2023 PSUs was amended so that, at vesting, the earned PSUs will be settled solely in cash equal to the market price of Bausch Health common shares, using the closing price on the vesting date. For executive Lisa Carson, an agreement provides that she will irrevocably surrender her 137,922 2023 PSUs in exchange for a cash amount based on the same market price definition.
The company notes that full details of the Appio and Carson agreements will be included as exhibits to its Form 10‑Q for the quarter ending March 31, 2026.
BHC reported a Form 144 notice indicating a proposed sale of 6,856 common shares through Fidelity Brokerage Services LLC on 03/02/2026 for exchange listing NYSE. The filing also shows a recent disposition of 8,388 common shares on 02/27/2026 for $49,908.60.
LEE STEVEN HYOSIG reported acquisition or exercise transactions in this Form 4 filing.
Bausch Health Companies Inc. reported that senior vice president, controller and chief accounting officer Steven Hyosig Lee received an equity grant in the form of restricted share units. He was awarded 45,868 common share RSUs at no purchase price, which will vest in three equal annual installments.
These units vest one-third on each of the first three anniversaries of the grant date, conditional on his continued service. Once vested, each RSU will be settled in one common share of Bausch Health. Following this grant, his directly held common shares total 73,239.
Bausch Health Companies Inc. executive Aimee J. Lenar reported equity compensation changes in company common shares. She received a grant of 157,139 restricted share units at $0.0000 per share on February 25, 2026, increasing her direct holdings to 417,913 shares.
These RSUs vest one-third on each of the first three anniversaries of the grant date, contingent on continued service, and are settled in common shares. On February 26, 2026, 17,578 common shares valued at $6.04 per share were withheld to cover tax obligations upon RSU vesting, leaving her with 400,335 directly held shares.
Bausch Health Companies Inc. executive vice president and general counsel Seana Carson reported several equity transactions in company common shares. Carson received an award of 212,350 restricted share units (RSUs), which will vest in three equal annual installments, with vested RSUs settled in common shares.
To cover tax withholding on a prior RSU vesting, 32,211 common shares were withheld and disposed of at $6.04 per share. Carson also completed an open-market sale of 8,388 common shares at $5.95 per share pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on May 7, 2025. After these transactions, Carson directly holds 809,258 common shares of Bausch Health.
Bausch Health Companies Inc. EVP and CFO Jean-Jacques Charhon reported equity compensation and related tax withholding in this insider filing. On February 25, 2026, he acquired 276,055 restricted share units (RSUs) for no cash consideration. These RSUs vest one-third on each of the first three anniversaries of the grant date, and vested RSUs are settled in Bausch Health common shares.
On February 26, 2026, 35,977 common shares were disposed of at $6.04 per share to satisfy tax withholding obligations upon RSU vesting, rather than as an open-market sale. After these transactions, Charhon directly held 755,538 common shares of Bausch Health.